|
Naloxegol for patients with cancer pain diagnosed with opioid induced constipation (OIC): NACASY observational study. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chr. Hansen; Ironwood Pharmaceuticals; Zealand Pharmaceuticals |
Consulting or Advisory Role - Alfa Wassermann; Allergan; Danone; Grunenthal; Janssen; Kyowa Kirin International; Menarini; Mylan; Neutec; Novartis; Noventure; Nutricia; Shionogi; Shire; Takeda; Theravance; Tramedico; Truvion Healthcare; Tsumura & Co.; Zeria Pharmaceutical |
Speakers' Bureau - Abbott; Allergan; AstraZeneca; Janssen; Kyowa Kirin International; Menarini; Mylan; Novartis; Shire; Takeda; Truvion Healthcare; Zeria Pharmaceutical |
Research Funding - Shire; Sofar; Tsumura & Co. |
Expert Testimony - FDA hearing for prucalopride; Shire |
|
|
Employment - Kyowa Kirin International |
|
|
Employment - Kyowa Kirin International |
|
|
No Relationships to Disclose |